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Introduction: Double-unit umbilical cord blood trans-
plantation (dCBT) is a validated strategy to broaden access to
hematopoietic stem cell transplantation (HSCT), but is
limited by delayed engraftment and immune reconstitution.
ATG is a part of conventional myeloablative (MA) condi-
tioning for CBT, and although it may facilitate engraftment, it
can also contribute to delayed immune reconstitution
through T-cell depletion. We conducted a Phase II trial to
assess the safety and efﬁcacy of dCBT following a preparative
regimen combining total lymphoid irradiation (TLI, 400 cGy)
in lieu of ATG, with Fludarabine/Busulfan 3.2mg/kg IV x4
(FluBu4). Tacrolimus and mycophenolate mofetil were used
as GVHD prophylaxis.
Methods and Results: Twenty consecutive patients with
hematological malignant or non-malignant disorders were
enrolled between 2008 and 2012 at the University of Mich-
igan Blood and Marrow Transplantation Program. Trans-
plants consisted of two umbilical cord blood (UCB) units that
were at least a 4/6 HLA match to the pt, and 3/6 match to
each other. Median age was 49 yrs (range, 13-64 yrs). Most
patients had AML in CR1 or CR2 (40%), followed by NHL in PR
or better (25%), MDS (20%), ALL in early relapse (5%), MM in
VGPR (5%), and aplastic anemia (5%). Median HCT-CI pre-
transplant was 3 (0-7). Median total cells infused were
5.3x10
ˇ
7 (4-15.6x10
ˇ
7) of recipient body wt. Neutrophil
engraftment occurred in 85% of pts (95% CI, 60-95%), at a
median of 16 days (12-31), and 14/17 patients engrafted
within 26 days. Platelet engraftment occurred in 65% of pts
(95% CI, 40-82%) at a median of 43 days (26-86). Cumulative
incidences of grade II-IV and grade III/IV acute GVHD was
35% and 10%, respectively, and cumulative incidence of
chronic GVHD at 1 year was 25%. Relapse was the primary
cause of death and occurred in 6 pts (30%), all within 1 yr. At
days 100 and 365, cumulative incidence of TRM was 25%
(95% CI, 9-45%) and 35% (95% CI, 16-55%) respectively.
Transplant-related mortality trended to pts >50 yrs
(p¼0.058). The cause of TRM was GVHD in 5 patients and
graft failure in 2 patients. Two GVHD deaths resulted from
HSV-2 or HHV6 viremia while receiving high dose steroids.
OS at 1 year was 40% (95% CI, 19-60%), and 7 (35%) are in CR
after median follow up of 2.35 years post-transplant.
Conclusion: In summary, dCBT after MA conditioning with
FluBu4/TLI provides high engraftment rates with early
neutrophil recovery. Although conclusions regarding sur-
vival are limited due to sample size, this seemed to be in line
with previous reports, and was clearly better for younger
patients (<50 years old).321
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Introduction: HSCT is the only potentially curative therapy
for a well-selected group of patients with MDS. The objective
of this work was to describe a single center experience over
the past 15 years with HSCT in MDS patients.
Materials and Methods: Retrospective descriptive.
Patients: From 1997 to May 2013, 19 transplants have been
performed in 18 patients. 11 were male; mean age was 45
years (range 31-62).
11 patients had marrow failure as predominantly clinical
presentation; only one of these patients had not hadmultiple
transfusions at the time of transplantation. 5 patients were in
ﬁrst complete remission after induction chemotherapy. Only
3 patients received hypomethylating therapy before trans-
plantation. Median time from diagnosis to transplant was
296 days (range 58-950).
Results: PBSC fromHLA identical sibling donors where use in
18 transplants. One patient received PBSC from an HLA
identical URD. Conditioning treatment consisted on Fludar-
abine-PO Busulfán (11) or PO Busulfan-Cyclosphosphamide
(4) in the majority of patients. GVHD prophylaxis was per-
formed with Cyclosporine-MMF(10) or Cyclosporine-MTX
(5) in most cases.
17 patients engrafted; one patient had a primary graft
failure, which was rescued with a second transplant from the
same donor that also failed.
Mean CD34+ infused were 3.5 (range 1.05-4.64), mean
neutrophil graft was on day +12 (range 10-16), 4 patients (22
%) died before day 100 (graft failure, alveolar hemorrhage,
relapse, liver failure). 3 patients died after the 100th day, all
in relation to GVHD. With a median follow up of 24.1 months
(range: 0.7-89.1), overall survival was 61 %. GVHD was the
most frequent cause of death. 5 of the 7 deaths occurred in
the ﬁrst year.
Conclusion: The HSCT is a curative strategy for a signiﬁcant
percentage of patients with MDS.322
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